AOD-9604 vs. DSIP

Category

Growth

Research other

CAS no.

221231-10-3

62568-57-4

Molecular weight

1815.09 g/mol

848.81 g/mol

Half-life

0.4 h

0.1 h

Sequence

AOD-9604

AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.

DSIP

DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.

Highest evidence

Studies

3

4

of which in humans

2

1

Effects recorded

3

3

Open conflicts

1

1

Documented adverse events

1

1